Details of the Drug

General Information of Drug (ID: DMFI46A)

Drug Name
Argatroban
Synonyms
Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Approved [1]
Therapeutic Class
Anticoagulants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 508.6
Logarithm of the Partition Coefficient (xlogp) 1.3
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 100% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 5 mL/min/kg [3]
Elimination
16% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 39 and 51 minutes [3]
Metabolism
The drug is metabolized via the liver []
Unbound Fraction
The unbound fraction of drug in plasma is 0.46% [3]
Vd
The volume of distribution (Vd) of drug is 0.174 L/kg []
Chemical Identifiers
Formula
C23H36N6O5S
IUPAC Name
(2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
Canonical SMILES
C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
InChI
InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
InChIKey
KXNPVXPOPUZYGB-IOVMHBDKSA-N
Cross-matching ID
PubChem CID
92722
ChEBI ID
CHEBI:94385
CAS Number
74863-84-6
DrugBank ID
DB00278
TTD ID
D07UWV
INTEDE ID
DR0132

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Inhibitor [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Thrombosis
ICD Disease Classification DB61-GB90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Argatroban
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Argatroban and Apixaban. Thrombosis [DB61-GB90] [6]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Argatroban and Cangrelor. Thrombosis [DB61-GB90] [6]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Argatroban and Brilinta. Thrombosis [DB61-GB90] [6]
Clopidogrel DMOL54H Major Increased risk of bleeding by the combination of Argatroban and Clopidogrel. Thrombosis [DB61-GB90] [7]
Coadministration of a Drug Treating the Disease Different from Argatroban (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cilostazol DMZMSCT Major Increased risk of bleeding by the combination of Argatroban and Cilostazol. Arterial occlusive disease [BD40] [7]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Argatroban and Pentosan polysulfate. Chronic pain [MG30] [8]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Argatroban and Phenylbutazone. Chronic pain [MG30] [7]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Argatroban and Ketoprofen. Chronic pain [MG30] [7]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Argatroban and Levomilnacipran. Chronic pain [MG30] [9]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Argatroban and Anisindione. Coagulation defect [3B10] [10]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Argatroban and Regorafenib. Colorectal cancer [2B91] [6]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Argatroban and Intedanib. Colorectal cancer [2B91] [11]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Argatroban and Ardeparin. Coronary thrombosis [BA43] [12]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Argatroban and Danaparoid. Deep vein thrombosis [BD71] [12]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Argatroban and Rivaroxaban. Deep vein thrombosis [BD71] [13]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Argatroban and Sertraline. Depression [6A70-6A7Z] [9]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Argatroban and Fluoxetine. Depression [6A70-6A7Z] [9]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Argatroban and Vilazodone. Depression [6A70-6A7Z] [9]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Argatroban and Paroxetine. Depression [6A70-6A7Z] [9]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Argatroban and Vortioxetine. Depression [6A70-6A7Z] [9]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Argatroban and Duloxetine. Depression [6A70-6A7Z] [9]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Argatroban and Milnacipran. Depression [6A70-6A7Z] [9]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Argatroban and Desvenlafaxine. Depression [6A70-6A7Z] [9]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Argatroban and Clomipramine. Depression [6A70-6A7Z] [9]
Venlafaxine DMR6QH0 Moderate Increased risk of bleeding by the combination of Argatroban and Venlafaxine. Depression [6A70-6A7Z] [9]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Argatroban and Heme. Discovery agent [N.A.] [14]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Argatroban and Apigenin. Discovery agent [N.A.] [15]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Argatroban and PMID28870136-Compound-49. Discovery agent [N.A.] [16]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Argatroban and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [9]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Argatroban and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [17]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Argatroban and Mefenamic acid. Female pelvic pain [GA34] [7]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Argatroban and Avapritinib. Gastrointestinal stromal tumour [2B5B] [6]
Sulfinpyrazone DMEV954 Major Increased risk of bleeding by the combination of Argatroban and Sulfinpyrazone. Gout [FA25] [7]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Argatroban and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Dipyridamole DMXY30O Major Increased risk of bleeding by the combination of Argatroban and Dipyridamole. Hypertension [BA00-BA04] [7]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Argatroban and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [7]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Argatroban and Acalabrutinib. Mature B-cell lymphoma [2A85] [19]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Argatroban and Ibrutinib. Mature B-cell lymphoma [2A85] [20]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Argatroban and Ponatinib. Mature B-cell lymphoma [2A85] [21]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Argatroban and Panobinostat. Multiple myeloma [2A83] [22]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Argatroban and Fedratinib. Myeloproliferative neoplasm [2A20] [7]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Argatroban and Dasatinib. Myeloproliferative neoplasm [2A20] [23]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Argatroban and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [8]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Argatroban and Prasugrel. Myocardial infarction [BA41-BA43] [6]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Argatroban and Vorapaxar. Myocardial infarction [BA41-BA43] [24]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Argatroban and Tirofiban. Myocardial infarction [BA41-BA43] [7]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Argatroban and Sibutramine. Obesity [5B80-5B81] [9]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Argatroban and Dexfenfluramine. Obesity [5B80-5B81] [9]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Argatroban and Diclofenac. Osteoarthritis [FA00-FA05] [7]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Argatroban and Nepafenac. Osteoarthritis [FA00-FA05] [17]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Argatroban and Naproxen. Osteoarthritis [FA00-FA05] [7]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Argatroban and MK-4827. Ovarian cancer [2C73] [6]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Argatroban and Aspirin. Pain [MG30-MG3Z] [7]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Argatroban and Etodolac. Pain [MG30-MG3Z] [7]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Argatroban and Diflunisal. Pain [MG30-MG3Z] [7]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Argatroban and Ibuprofen. Pain [MG30-MG3Z] [7]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Argatroban and Nabumetone. Pain [MG30-MG3Z] [7]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Argatroban and Piroxicam. Pain [MG30-MG3Z] [7]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Argatroban and Choline salicylate. Postoperative inflammation [1A00-CA43] [25]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Argatroban and Ketorolac. Postoperative inflammation [1A00-CA43] [7]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Argatroban and Bromfenac. Postoperative inflammation [1A00-CA43] [7]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Argatroban and Treprostinil. Pulmonary hypertension [BB01] [26]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Argatroban and Epoprostenol. Pulmonary hypertension [BB01] [26]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Argatroban and Iloprost. Pulmonary hypertension [BB01] [26]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Argatroban and Salsalate. Rheumatoid arthritis [FA20] [25]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Argatroban and Meloxicam. Rheumatoid arthritis [FA20] [7]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Argatroban and Sulindac. Rheumatoid arthritis [FA20] [7]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Argatroban and Oxaprozin. Rheumatoid arthritis [FA20] [7]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Argatroban and Flurbiprofen. Rheumatoid arthritis [FA20] [7]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Argatroban and Fenoprofen. Rheumatoid arthritis [FA20] [7]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Argatroban and Indomethacin. Rheumatoid arthritis [FA20] [7]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Argatroban and Tolmetin. Rheumatoid arthritis [FA20] [7]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Argatroban and Salicyclic acid. Seborrhoeic dermatitis [EA81] [27]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Argatroban and Curcumin. Solid tumour/cancer [2A00-2F9Z] [28]
Warfarin DMJYCVW Major Increased risk of bleeding by the combination of Argatroban and Warfarin. Supraventricular tachyarrhythmia [BC81] [10]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Argatroban and Caplacizumab. Thrombocytopenia [3B64] [22]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Argatroban and Cabozantinib. Thyroid cancer [2D10] [29]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Argatroban and Betrixaban. Venous thromboembolism [BD72] [30]
⏷ Show the Full List of 74 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6385).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
5 Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
6 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7 Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
8 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
9 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
10 Bates ER, Mukherjee D, Lau WC "Drug-drug interactions involving antiplatelet agents." Eur Heart J 24 (2003): 1707-9. [PMID: 14522564]
11 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
12 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
13 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
14 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
15 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
16 Canadian Pharmacists Association.
17 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
18 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
19 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
20 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
21 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
22 Cerner Multum, Inc. "Australian Product Information.".
23 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
24 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
25 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
26 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
27 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
28 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
29 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
30 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.